Can Virion’s T-cell immunotherapy help achieve a functional hepatitis B cure?
Virion Therapeutics will present extended Phase 1b follow-up for VRON-0200 at AASLD 2026. Earlier published results showed continued hepatitis B surface antigen declines in most patients receiving the experimental immunotherapy alone, but a functional cure has not been established.